Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.
[EN] HPK1 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE HPK1 ET LEURS UTILISATIONS
申请人:QILU REGOR THERAPEUTICS INC
公开号:WO2021000935A1
公开(公告)日:2021-01-07
Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.
Synthetic Entries to Substituted Bicyclic Pyridones
The synthesis of 6,6- and 5,6-bicyclic pyridone scaffolds has been completed using (i) an intramolecular Mitsunobu reaction and/or (ii) hydrolysis of a bicyclic pyridinium salt intermediate. Regioselective functionalization of the pyridone ring has been achieved via either direct lithiation or use of the "halogen dance" reaction. Suzukicoupling then allows introduction of aryl units at C(7)/C(9) or